We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+19.96%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.69%
AUM
$13.1B
AUM Growth
+$1.42B
(+12%)
Cap. Flow
-$642M
Cap. Flow
% of AUM
-4.89%
Top 10 Holdings %
Top 10 Hldgs %
18.52%
Holding
284
New
44
Increased
49
Reduced
142
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$163M |
| 2 |
Caterpillar
CAT
|
+$85.4M |
| 3 |
Analog Devices
ADI
|
+$53.7M |
| 4 |
Advance Auto Parts
AAP
|
+$39.7M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$142M |
| 2 |
Costco
COST
|
+$77.5M |
| 3 |
Vail Resorts
MTN
|
+$76.9M |
| 4 |
CELG
Celgene Corp
CELG
|
+$73.2M |
| 5 |
Mettler-Toledo International
MTD
|
+$67.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.26% |
| 2 | Healthcare | 16.35% |
| 3 | Consumer Discretionary | 13.11% |
| 4 | Industrials | 12.97% |
| 5 | Financials | 10.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Sarepta Therapeutics
SRPT
$1.78B
| $34.7M | 0.26% |
291,487
+36,385
| +14% | +$4.68M |
|
127
East-West Bancorp
EWBC
$18.1B
| $34M | 0.26% |
708,453
+220,803
| +45% | +$11.3M |
|
|
XYZ
128
Block Inc
XYZ
$47.3B
| $33.8M | 0.26% |
451,020
-4,369
| -1% | -$317K |
|
129
Charles River Laboratories
CRL
$12.5B
| $33.6M | 0.26% |
231,142
-3,535
| -2% | -$464K |
|
130
Diamondback Energy
FANG
$52.4B
| $33.5M | 0.26% |
330,082
-4,605
| -1% | -$472K |
|
131
Ryder
R
$10.1B
| $33M | 0.25% |
531,993
+111,030
| +26% | +$6.5M |
|
132
Twilio
TWLO
$36.7B
| $32.9M | 0.25% |
254,986
-61,182
| -19% | -$6.89M |
|
133
Skyworks Solutions
SWKS
$10.5B
| $32.7M | 0.25% |
396,790
+46,156
| +13% | +$3.56M |
|
134
RPM International
RPM
$14.9B
| $32.3M | 0.25% |
556,371
-108,798
| -16% | -$6.17M |
|
135
Newmark Group
NMRK
$2.65B
| $32M | 0.24% |
3,836,182
+1,280,562
| +50% | +$12.1M |
|
136
Ingevity
NGVT
$2.66B
| $31.6M | 0.24% |
299,354
-52,390
| -15% | -$5.26M |
|
137
Burlington
BURL
$23.2B
| $30.8M | 0.23% |
196,570
-70,430
| -26% | -$11.4M |
|
138
Mine Safety
MSA
$7.55B
| $30.7M | 0.23% |
296,985
-16,335
| -5% | -$1.65M |
|
139
Nexstar Media Group
NXST
$5.94B
| $30.6M | 0.23% |
282,482
-81,711
| -22% | -$7.54M |
|
140
Alnylam Pharmaceuticals
ALNY
$29.1B
| $29.9M | 0.23% |
319,923
+49,480
| +18% | +$4.14M |
|
141
Wolverine World Wide
WWW
$1.56B
| $29.8M | 0.23% |
832,800
+87,150
| +12% | +$3.04M |
|
142
Pultegroup
PHM
$25.3B
| $29.3M | 0.22% |
+1,047,575
| New | +$28.5M |
|
|
SIVB
143
DELISTED
SVB Financial Group
SIVB
| $28.4M | 0.22% |
127,673
-28,749
| -18% | -$6.69M |
|
|
ENV
144
DELISTED
ENVESTNET, INC.
ENV
| $27.9M | 0.21% |
427,230
+9,580
| +2% | +$551K |
|
145
Neurocrine Biosciences
NBIX
$16.6B
| $27.9M | 0.21% |
316,540
+172,800
| +120% | +$14.4M |
|
146
Gartner
IT
$11.7B
| $27.3M | 0.21% |
179,705
-46,551
| -21% | -$6.46M |
|
147
Lumentum
LITE
$69.6B
| $27.2M | 0.21% |
480,830
-7,210
| -1% | -$346K |
|
|
MASI
148
DELISTED
Masimo
MASI
| $27.1M | 0.21% |
195,947
-9,275
| -5% | -$1.16M |
|
149
Bright Horizons
BFAM
$3.88B
| $27.1M | 0.21% |
213,113
-14,260
| -6% | -$1.7M |
|
150
Lincoln Electric
LECO
$15.4B
| $26.9M | 0.2% |
320,998
+24,120
| +8% | +$2.05M |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Westfield Capital Management held 284 positions worth $13.1B, up 12% from $11.7B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Westfield Capital Management withdrew a net $642M in Q1 2019, closing 38 positions and reducing 142 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $142M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Westfield Capital Management opened a new position in Bristol-Myers Squibb worth $156M.
- Westfield Capital Management's largest Q1 2019 buy was Bristol-Myers Squibb: 3,278,241 shares worth $156M.
- Westfield Capital Management added most to T-Mobile US in Q1 2019, an estimated $32.3M increase.
- Westfield Capital Management's biggest Q1 2019 reduction was Vail Resorts, cutting an estimated $76.9M.
- Westfield Capital Management fully exited Jazz Pharmaceuticals in Q1 2019, selling an estimated $142M.
- Westfield Capital Management's ten largest holdings make up 19% of its $13.1B portfolio in Q1 2019.
- Westfield Capital Management opened 44 new positions and closed 38 in Q1 2019.
- Westfield Capital Management's portfolio value rose 12% quarter-over-quarter to $13.1B.
Based on Westfield Capital Management's 13F filing for Q1 2019, filed 14 May 2019.